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Our study proposes to investigate: whether 
there is a benefit to a formal screening 
recommendation and if so, at what point is it 
appropriate to screen for vitamin B12 
deficiency in patients on Metformin. 
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Metformin and Vitamin B12
● The first article describing this association was published in 1971 by Tomkin, Weaver and Montgomery.1
● Postulated theories 
● Alterations in small bowel motility which stimulates bacterial overgrowth and consequential vitamin B12 deficiency. 2
● Competitive inhibition or inactivation of vitamin B12 absorption. 2
● Alterations in intrinsic factor (IF) levels and interaction with the cubulin endocytic receptor. 2
● Metformin has also been shown to inhibit the calcium dependent absorption of the vitamin B12-IF complex at the terminal ileum. 2
● In a meta-analysis review of 19 intermediate or high quality rated studies, it was found that metformin treatment is significantly 
associated with an increase in incidence of vitamin B12 deficiency and reduced serum levels. This association was dose and duration 
dependent. 3
● A recent, randomized control trial designed to examine the temporal relationship between metformin and serum B12 found a 19% 
reduction in serum B12 levels compared with placebo after 4 years. Several other randomized control trials and cross-sectional surveys 
reported reductions in B12 ranging from 9 to 52%. 4
● Despite Metformin’s potential to cause vitamin B12 deficiency, there are no formal screening guidelines. 
● The 2018 American Diabetes Association Standards of Medical Care position statement reports: “Long-term use of metformin may be 
associated with biochemical vitamin B12 deficiency, and periodic measurement of vitamin B12 levels should be considered in metformin-
treated patients, especially in those with anemia or peripheral neuropathy. (Grade B)”. 5
● No formal recommendations have been provided by USPSTF.
● The Agency for Healthcare Research and Quality recommended that physicians consider screening patients for Vitamin B12 deficiency on 
long term PPI or H2 blockers (>12 months) and metformin (>4 months). 6
Study Design and Protocol 
• This study is pending IRB approval (common rule changes 
impacting approval)
• Retrospective cohort study relying on existing 
administrative data without patient contact
• Study Population: Patients with HAP insurance who were 
exposed to Metformin
• Comparison Population: Patients with HAP insurance 
unexposed to Metformin 
Attrition Diagram For Exposed Population 
16,921
20,293
● Age <18 y/o
● Pre-existing B12 deficiency 
● Less than 1 year of Metformin 
● Metformin within 30 days of enrollment with 
HAP (concern for prior use under a different 
insurance)
13,489
● Patients who filled only one prescription for 
Metformin 
Final Study Population
22,648
● Patients with HAP insurance on Metformin
Study Design and Protocol 
Outcome Variables: 
• B12 Testing 
• B12 Deficiency 
Variables: 
• MRN (Patients with metformin use)(All available doses, 
brands, and combination pills for various time periods) 
• Dates of Metformin prescriptions 
• Dates of Vitamin B12 lab results 
• Age: 
• Group 1 = 18-39
• Group 2 = 40-49
• Group 3 = 50-64
• Group 4 = 65-79
• Group 5 = >80 
• Gender: Male or Female 
• Race: Asian, African American, Caucasian, Hispanic, and 
Other
• PPI use
• Malabsorption disorder (small bowel disease, 
malnutrition, celiac disease, bariatric surgery)
Comparison Population
• Total number of HAP Patients not on Metformin who 
were tested for B12 deficiency : 90,693
• Total number of HAP Patients not on Metformin 
found to be B12 Deficient: 1,943
• Prevalence of B12 deficiency in patients not on 
metformin: 2.14%
● The overall incidence of vitamin B12 testing in our study was (6051 out of 13489, 
44.86%). 
● Our study demonstrated that the incidence of vitamin B12 deficiency in the exposed 
group (patients on metformin): 3.34% 
● The average time to test was 971 days, the average time to test positive was 1925 
days.
● Amongst the comparison group (patients not on metformin) the incidence of 
vitamin B12 deficiency was 2.14% 
● Relative risk : 3.34/2.14=1.6 
● Absolute risk increase = 0.0334 - 0.0214  = 0.012
● NNH= 1 / 0.012 = 83 
Results

Days to B12 test Days to B12 
deficiency 
detected
Shortest time to detection 1 51
25th percentile 296 1031 
(~3 years)
Mean 971
(2.9 years)
1926 
(5.2 years)
Median 720 2287
Discussion: Overview 
• Despite the evidence associating metformin use with low vitamin B12 levels, 
screening for B12 deficiency in individuals treated with metformin has not 
been incorporated into clinical practice guidelines
• Monitoring of vitamin B12 levels because of metformin use is rarely 
performed in our practice
● The only factor associated with deficiency in a multivariable analysis was 
older age
● African American ethnicity approached significance as a protective factor 
for B12 deficiency (p =0.051) 
Cost Analysis
Cost of routine B12 Testing 
• Total No. of Patients on Metformin: 22,648
• Cost/test: $ 80.00
• Frequency of  testing: Q 3 years
Cost of Empiric B12 treatment (oral/IM)
• Oral B12 cost/year/person: $24.00
• IM B12 cost/year/person: $84.00
Estimated cost burden of untreated Vit B12 Deficiency (over 15 
years)
● Total No. of Patients on Metformin: 22,648
● Total Cost Burden of Untreated B12 def. over 15 year: $50,000*
* Per data published in year 20007
Discussion: Cost analysis  
• The estimated cost of disease burden to our positively tested 
population (3.34%) is $37.8 M at the 15 year mark. 
• $9.4 M for those tested positive (25%) at 1031 days 
• The  cost for routine testing $9.0 M over 15 years
• $1.8 M at 3yrs 
• The cost empiric treatment over 15 years:
• $8.1M (oral)
• $28.5M (IM)
Screening Guidelines
Criteria for screening: 
● Disease is appropriate for screening
- Serious 
- Early treatment more beneficial 
- High prevalence of pre-clinical disease 
● Program feasible and effective
- Acceptability
- Cost-effectiveness
- Number of cases detected 
● Valid test available
Strengths of the study 
• Large sample size
• Included participants >18 years old 
• Did account for confounders ie. malabsorption, PPI use, and bariatric surgery
• Excluded pre-existing vitamin B12 deficiency, therefore we assessed incidence, not prevalence  
Limitations of the Study 
• Metformin dosing or quantity: study was not stratified based on dose, combination pills were included 
• Population: HAP Only: Selection bias does exist with HAP (premium insurance); includes few Medicare 
patients HAP population, not representative of the whole population 
• Metformin compliance cannot be verified; however did include participants who filled their prescriptions >2 
times
• Nutritional status of participants, vegans & vegetarians, participants taking supplements on their own not 
accounted for 
• Other unmeasured patient factors likely exist 
Conclusion
Although at this time we do not have enough evidence to implement 
B12 screening in patients on metformin, we hope this study 
encourages physicians to think of the association between the two in 
their practice. 
Will you change your clinical practice 
based on this data? 
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